OTC: NURPF - Neuren Pharmaceuticals Limited

Lønnsomhet i seks måneder: -44.79%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Neuren Pharmaceuticals Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares.

flere detaljer
Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.neurenpharma.com
Цена ао 10.33
Prisendring per dag: 0% (7.868)
Prisendring per uke: 0% (7.868)
Prisendring per måned: -1.03% (7.95)
Prisendring over 3 måneder: -23.83% (10.33)
Prisendring over seks måneder: -44.79% (14.25)
Prisendring per år: -53.66% (16.98)
Prisendring over 3 år: +199.1% (2.6306)
Prisendring over 5 år: +842.28% (0.835)
Prisendring over 10 år: 0% (7.868)
Prisendring siden begynnelsen av året: -17.18% (9.5)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 12.7 1
P/BV 14.35 1
P/E 18.75 7
EV/EBITDA 14.7 7
Total: 5.63

Effektivitet

Navn Betydning Karakter
ROA, % 63.35 10
ROE, % 76.55 10
Total: 8.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA 0 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 46756.97 10
Lønnsomhet Ebitda, % -1821.79 0
Lønnsomhet EPS, % -2025.02 0
Total: 2
Flere detaljer

Institusjoner Volum Dele, %
Vanguard International Stock Index-Total Intl Stock Indx 1480133 1.16
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 877162 0.69
iShares Core MSCI EAFE ETF 652944 0.51
iShares MSCI EAFE Small Cap ETF 436465 0.34
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 403572 0.32
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 215442 0.17
iShares Core MSCI Total International Stock ETF 140892 0.11
Vanguard International Stock Index-Pacific Stock Index 128668 0.1
College Retirement Equities Fund-Stock Account 85378 0.07
SEI Institutional International Tr-International Equity 71485 0.06



Veileder Stillingstittel Betaling Fødselsår
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director 714.28k
Ms. Lauren Frazer C.A. CFO & Company Secretary N/A
Mr. Lawrence Glass BA (Biology) Chief Science Officer N/A
Mr. Gerry Zhao Vice President of Corporate Development N/A
Dr. Liza A. Squires M.D. Chief Medical Officer N/A

Adresse: Australia, Camberwell, 697 Burke Road - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.neurenpharma.com